Merck Cancidas Phase IV Studies Of Higher Doses To Conclude In 2005
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck has agreed to evaluate Cancidas doses above the approved 50 mg daily dose in three studies as part of its Phase IV commitments for the antifungal.